vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.
TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $12.6M, roughly 1.7× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 7.5%, a 243.2% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 17.7%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 68.8%).
Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.
SPRO vs TRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $21.1M |
| Net Profit | $31.5M | $1.6M |
| Gross Margin | — | 30.6% |
| Operating Margin | — | 10.9% |
| Net Margin | 250.7% | 7.5% |
| Revenue YoY | 24080.8% | 17.7% |
| Net Profit YoY | 250.9% | -64.7% |
| EPS (diluted) | $0.56 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $21.1M | ||
| Q3 25 | $0 | $12.0M | ||
| Q2 25 | $0 | $8.3M | ||
| Q1 25 | $12.0K | $8.2M | ||
| Q4 24 | $52.0K | $17.9M | ||
| Q3 24 | $65.0K | $10.9M | ||
| Q2 24 | $114.0K | $5.7M | ||
| Q1 24 | $140.0K | $7.4M |
| Q4 25 | $31.5M | $1.6M | ||
| Q3 25 | $-7.4M | $1.7M | ||
| Q2 25 | $-1.7M | $-1.7M | ||
| Q1 25 | $-13.9M | $-1.5M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-17.1M | $-1.8M | ||
| Q2 24 | $-17.9M | $957.0K | ||
| Q1 24 | $-12.7M | $-914.0K |
| Q4 25 | — | 30.6% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | — | 45.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | — | -48.8% | ||
| Q1 25 | -122758.3% | -50.7% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | -28604.6% | -34.9% | ||
| Q2 24 | -16720.2% | -62.4% | ||
| Q1 24 | -9987.1% | -53.8% |
| Q4 25 | 250.7% | 7.5% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | — | -20.6% | ||
| Q1 25 | -115550.0% | -17.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | -26380.0% | -16.9% | ||
| Q2 24 | -15668.4% | 16.8% | ||
| Q1 24 | -9049.3% | -12.3% |
| Q4 25 | $0.56 | $0.05 | ||
| Q3 25 | $-0.13 | $0.06 | ||
| Q2 25 | $-0.03 | $-0.06 | ||
| Q1 25 | $-0.25 | $-0.05 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | $-0.32 | $-0.07 | ||
| Q2 24 | $-0.33 | $0.04 | ||
| Q1 24 | $-0.24 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $9.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $475.2M |
| Total Assets | $68.9M | $630.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | $9.5M | ||
| Q3 25 | $48.6M | $3.6M | ||
| Q2 25 | $31.2M | $2.5M | ||
| Q1 25 | $48.9M | $12.3M | ||
| Q4 24 | $52.9M | $39.3M | ||
| Q3 24 | $76.3M | $27.4M | ||
| Q2 24 | $63.5M | $33.0M | ||
| Q1 24 | $82.3M | $35.6M |
| Q4 25 | $59.0M | $475.2M | ||
| Q3 25 | $26.5M | $473.2M | ||
| Q2 25 | $32.8M | $471.5M | ||
| Q1 25 | $33.8M | $472.5M | ||
| Q4 24 | $46.1M | $473.6M | ||
| Q3 24 | $65.5M | $468.3M | ||
| Q2 24 | $80.5M | $469.2M | ||
| Q1 24 | $96.2M | $467.4M |
| Q4 25 | $68.9M | $630.5M | ||
| Q3 25 | $54.2M | $629.6M | ||
| Q2 25 | $62.1M | $618.5M | ||
| Q1 25 | $77.7M | $614.6M | ||
| Q4 24 | $110.5M | $608.0M | ||
| Q3 24 | $135.2M | $598.0M | ||
| Q2 24 | $149.9M | $590.8M | ||
| Q1 24 | $167.7M | $581.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $6.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.26× | 3.88× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $6.1M | ||
| Q3 25 | $17.4M | $-2.4M | ||
| Q2 25 | $-17.7M | $-381.0K | ||
| Q1 25 | $-4.0M | $-1.3M | ||
| Q4 24 | $-23.4M | $14.3M | ||
| Q3 24 | $12.8M | $2.1M | ||
| Q2 24 | $-18.7M | $-1.8M | ||
| Q1 24 | $5.9M | $777.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-14.6M | ||
| Q2 25 | — | $-20.0M | ||
| Q1 25 | — | $-18.9M | ||
| Q4 24 | — | $-42.9M | ||
| Q3 24 | — | $-16.8M | ||
| Q2 24 | — | $-15.8M | ||
| Q1 24 | — | $-7.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | -122.2% | ||
| Q2 25 | — | -240.6% | ||
| Q1 25 | — | -230.1% | ||
| Q4 24 | — | -239.3% | ||
| Q3 24 | — | -155.2% | ||
| Q2 24 | — | -277.2% | ||
| Q1 24 | — | -99.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 102.3% | ||
| Q2 25 | — | 236.0% | ||
| Q1 25 | — | 213.7% | ||
| Q4 24 | — | 319.1% | ||
| Q3 24 | — | 174.3% | ||
| Q2 24 | — | 245.5% | ||
| Q1 24 | — | 109.5% |
| Q4 25 | -0.26× | 3.88× | ||
| Q3 25 | — | -1.43× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.88× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
